KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma

OBJECTIVES: There is no molecular biomarker available in the clinical practice to assess the prognosis of advanced pancreatic carcinoma. This multicenter prospective study aimed to investigate the role of KRAS mutation subtypes within the primary tumor to determine the prognosis of advanced pancreat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Transl Gastroenterol
Autors principals: Bournet, Barbara, Muscari, Fabrice, Buscail, Camille, Assenat, Eric, Barthet, Marc, Hammel, Pascal, Selves, Janick, Guimbaud, Rosine, Cordelier, Pierre, Buscail, Louis
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2016
Matèries:
Original Contributions
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4822095/
https://ncbi.nlm.nih.gov/pubmed/27010960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ctg.2016.18
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars